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Abstract The objective of this study was to examine the
correlation between gene expression and lead (Pb) levels in
blood in children with autism (AU, n = 37) compared to
typically developing controls (TD, n = 15). We postulated
that, though lead levels did not differ between the groups,
AU children might metabolize lead differently compared to
TD children. RNA was isolated from blood and processed
on Affymetrix microarrays. Separate analyses of covari-
ance (ANCOVA) corrected for age and gender were
performed for TD, AU, and all subjects (AU ? TD). To
reduce false positives, only genes that overlapped these three
ANCOVAs were considered. Thus, 48 probe sets correlated
with lead levels in both AU and TD subjects and were
significantly different between the groups (p(Diagnosis 9
log2 Pb) \ 0.05). These genes were related mainly to
immune and inflammatory processes, including MHC
Class II family members and CD74. A large number
(n = 791) of probe sets correlated (P B 0.05) with lead
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levels in TD but not in AU subjects; and many probe sets
(n = 162) correlated (P B 0.05) with lead levels in AU but
not in TD subjects. Only 30 probe sets correlated
(P B 0.05) with lead levels in a similar manner in the AU
and TD groups. These data show that AU and TD children
display different associations between transcript levels and
low levels of lead. We postulate that this may relate to the
underlying genetic differences between the two groups,
though other explanations cannot be excluded.
Keywords Blood  Lead  Heavy metals  Autism 
Microarrays  Genes
Introduction
Lead (Pb) is a worldwide environmental health hazard that
poses a substantial risk to children and adults. The nervous,
immune, renal, skeletal, and hematopoetic systems can be
affected by lead exposure (Bouton and Pevsner 2000;
Landrigan and Todd 1994). The nervous system of children
is more sensitive to the toxic effects of lead compared to
adults (Needleman 2004). Pediatric lead exposure can
affect the development of cognitive, communication, and
social functions (Lidsky and Schneider 2003; Gilbert et al.
2005). Some studies have suggested that even low levels of
lead can affect children (Needleman 2004; Lanphear 2007;
Needleman 2009). Lead, a xenobiotic not known to be a
natural component of any biological system, competes with
biologically essential metals such as calcium and zinc in
metal-binding domains of enzymes, transcription factors,
and other proteins (Bouton and Pevsner 2000; Needleman
2004; Yoon et al. 2008). These effects, along with the
associated oxidative stress (Adonaylo and Oteiza 1999),
likely contribute to lead-induced changes of gene expres-
sion in cells (Bouton and Pevsner 2000; Yoon et al. 2008).
Autism (AU) is a developmental disorder characterized
by impaired communication, social interactions, and
abnormally restricted and repetitive behavior. The etiology
of AU may involve a complex combination of environ-
mental, neurological, immunological, and genetic factors
(London 2000; Hertz-Picciotto et al. 2006; Ashwood et al.
2006). Though many studies show that lead is neurotoxic,
lead has not been implicated in AU. Recent studies suggest
that lead exposure when compounded by environmental
stress may increase nervous system susceptibility to lead
(Virgolini et al. 2005, 2006; White et al. 2007; Cory-Sle-
chta 2005; Cory-Slechta et al. 2004). If true, one might
consider AU as a form of ‘‘stress’’ that could alter the
metabolism to heavy metal toxicants in children with AU
compared to typically developing (TD) children. Previ-
ously, using genome wide RNA expression microarrays,
we demonstrated that expression (RNA levels) of specific
genes in peripheral blood differed between AU and TD
controls (Gregg et al. 2008). In this report, we use genome
wide RNA expression microarrays to examine the associ-
ation between gene expression and lead levels in peripheral




All of the participating children were recruited as part of
the Childhood Autism Risks from Genetics and Environ-
ment (CHARGE) study at University of California at
Davis. A full description of the study, including recruit-
ment and the assessment criteria, has been published
(Hertz-Picciotto et al. 2006). AU diagnoses were assessed
using the Autism Diagnostic Interview-Revised (ADI-R)
(Lord et al. 1994, 1997), and the Autism Diagnostic
Observation Schedules (ADOS, Lord et al. 2000, 2003).
The final diagnosis of AU was defined as meeting criteria
on the communication, social, and repetitive behavior
domains of the ADI-R, and scoring at or above the total
cutoff for autistic disorder on the ADOS module 1 or 2.
The TD controls were randomly sampled from California
state birth certificate files. The Social Communication
Questionnaire, Mullen Scales of Early Learning and
Vineland Adaptive Behavioral Scales, along with a
developmental pediatrician interview and examination
were used to exclude putative TD subjects with behav-
ioral, developmental or autism spectrum disorder (ASD)
abnormalities.
There were 37 children with AU and 15 TD children
from the general population in this study. The average age
of AU subjects was 44.2 ± 10 months and that for TD was
41.2 ± 6 months, which was not significantly different
(t-test, P [ 0.05). There were 32 males and 5 females in
the AU group of whom 17 were Hispanic, 16 were white
and 4 were other races. There were 11 males and 4 females
in the TD group of whom 8 were Hispanic, 5 were Cau-
casian, and 2 were other races. The male predominance
reflects the prevalence of the AU in males being higher
than females (Hertz-Picciotto et al. 2006; Gillberg and
Wing 1999) and the CHARGE study matching of popula-
tion controls to the projected sex ratio of cases. We
included both male and female subjects and corrected
gender effects in the analyses.
Blood Lead Measurement
Blood samples for lead were collected in ethylenediami-
netetraacetic acid (EDTA) vacutainer tubes. A portion of
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the blood (0.5 ml) designated for metal analysis was then
stored at -20C. Lead was measured using an Agilent
7500i (Palo Alto, CA) Inductively Coupled Plasma Mass
Spectrometer (ICP-MS) in the Department of Civil and
Environmental Engineering, UC Davis. Detailed methods
were included in a previous publication (Hertz-Picciotto
et al. 2009). Samples were thawed and diluted 20-fold with
water containing 1% nitric acid (trace metal grade, Fisher
Scientific, Pittsburgh, PA), 0.05% Triton x-100 (Fisher),
and 100 ppb Tb (Spex Certiprep, Methuen, NJ) as an
internal standard. Samples were loaded at 0.4 ml/min using
a peri-staltic pump with 1.2 l/min Argon (Ar) carrier gas
through a Babbington-style nebulizer into a Peltier-cooled
double-pass spray-chamber at 2C. Then, 1 l/min auxiliary
Ar and 12 l/min plasma gas Ar were added for a total of
14 l/min and separated from Ni cones by a sampling depth
of 8.5 mm. Validation used the Performance Testing
standards from New York State (Wadsworth Center). The
limit of detection (LOD) for lead was 0.006 lg/dl.
RNA Isolation and Microarray Processing
RNA isolation and microarray processing were performed
as described previously (Gregg et al. 2008). Briefly, 15 ml
blood was collected into six PAXgene vacutainer tubes
(Qiagen; Valencia, CA). Total RNA was isolated using the
PAXgene blood RNA kit (Qiagen; Valencia, CA) accord-
ing to the manufacturer’s instructions. RNA quality and
purity were analyzed by spectrophotometry using the
Nanodrop ND-1000, and RNA integrity was analyzed
using the Agilent 2100 Bioanalyzer. Samples achieved
A260/A280 absorbance ratios of purified RNA exceeding
2.0, the 28S/18S rRNA ratios were equal to or exceeded
1.5, and the RNA Intergrated Number (RIN) exceeded 8.0.
Gene expression was assessed on the Human U133 Plus 2.0
GeneChip microarrays (Affymetrix; Santa Clara, CA)
according to the standard Affymetrix expression analysis
protocols. The microarrays detected over 54,000 probe sets
which assessed over 38,500 human genes (Affymetrix
manual). In our study, we use the term ‘‘probe sets’’ for a
designated group of oligonucleotides on a microarray, and
the term ‘‘genes’’ for known, annotated genes.
Statistical Analyses
The analyses were performed using Partek Genomics Suite,
version 6.4, release 6.09.0422 (Partek Inc., St. Louis, MO,
USA). Gene expression data were normalized using
GC-RMA. Analysis of covariance (ANCOVA) was per-
formed and the partial correlations were estimated between
gene expression and log2-transformed lead levels, while
controlling the effects of age and gender. The partial cor-
relation is the correlation that remains between the
dependent variable (gene expression) and the independent
variable of interest (log2 Pb) after removing the correlation
that is due to their mutual association with the other
independent variables (age and gender). We performed an
ANCOVA on the three models shown in Fig. 1. The
variables for these three models are:
• Model 1 (TD samples only): log2 Pb (continuous vari-
able), Age (continuous variable), Gender (categorical
variable).
• Model 2 (AU samples only): log2 Pb (continuous
variable), Age (continuous variable), Gender (categori-
cal variable).
Fig. 1 Venn diagrams showing the work flow for the statistical
analyses. GE gene expression; TD typically developing children from
the general population; AU Children with autism. Model 1 identified
genes whose expression significantly correlated (p(log2 Pb) \ 0.05)
with lead levels in TD after accounting for partial correlations for age
and gender. Model 2 identified genes whose expression significantly
correlated (p(log2 Pb) \ 0.05) with lead levels in AU after accounting
for partial correlations for age and gender. Model 3 identified genes
whose expression significantly differently correlated with lead levels
for AU compared to TD based on the interaction of diagnosis with
lead level after adjustment for age and gender. Gene list A represents
genes whose expression correlates significantly (p(log2 Pb) B 0.05)
with log2 Pb levels in each of AU and TD models separately, and the
partial correlation coefficients are significantly different from each
other in combined model(p(Diagnosis 9 log2 Pb) B 0.05). Gene list
B represents genes whose expression correlates (p(log2 Pb) B 0.05)
with log2 Pb levels in each of AU and TD models separately, but the
partial correlation coefficients are not significantly different from
each other in combined model. Gene list C represents genes whose
expression significantly correlates with log2 Pb levels in TD
(p(log2 Pb) B 0.05) but not in AU subjects, and the partial correlation
coefficients are significantly different from each other in combined
model (p(Diagnosis 9 log2 Pb) B 0.05). Gene list D represents genes
whose expression significantly correlates with log2 Pb levels in AU
(p(log2 Pb) B 0.05) but not in TD subjects, and the partial correlation
coefficients are significantly different from each other in combined
model (p(Diagnosis 9 log2 Pb) B 0.05)
Neurotox Res (2011) 19:1–13 3
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• Mode 3 (AU and TD samples combined): log2 Pb
(continuous variable), Age (continuous variable), Gen-
der (categorical variable), Diagnosis (categorical vari-
able), Diagnosis 9 log2 Pb (interaction).
In order to decrease the numbers of false positives, we
reasoned that the genes that demonstrated overlaps
between the ANCOVA Models would be the most reliable.
These gene overlaps are shown in Fig. 1 (ListA-D) and
represent the following:
• Gene list A represents genes whose expression corre-
lated with lead levels in each of AU and TD models
separately (p(log2 Pb) B 0.05), and the partial correla-
tion coefficients were statistically different between
the two groups in combined model (p(Diagnosis 9
log2 Pb) B 0.05).
• Gene list B represents genes whose expression corre-
lated with lead levels both in AU and TD models
separately (p(log2 Pb) B 0.05) without any significant
difference in the partial correlation coefficients between
the two groups in combined model (p(Diagnosis 9
log2 Pb) [ 0.05).
• Gene list C represents genes whose expression signifi-
cantly correlates with lead levels in TD (p(log2 Pb)
B 0.05) but not in AU models, and the partial correlation
coefficients were statistically different between the
two groups in combined model (p(Diagnosis 9
log2 Pb) B 0.05).
• Gene list D represents genes whose expression signifi-
cantly correlates with lead levels in AU (p(log2 Pb) B
0.05) but not in TD models, and the partial correlation
coefficients were statistically different between the two
groups in combined model (p(Diagnosis 9 log2 Pb) B
0.05).
As described above, each of these gene lists was
adjusted to account for partial correlations due to age and
gender. Gene list A ? C ? D contained genes, whose
expression differently correlated with blood lead levels,
only Gene list B contained genes, whose expression cor-
related with lead levels in a similar manner.
Assessment of Biological Significance of Identified
Genes
The network, molecular functions, and toxicant functions
were analyzed using Ingenuity Pathways Analysis (IPA,
Ingenuity Systems, www.ingenuity.com). The datasets
(gene lists) were uploaded into IPA. Each identifier was
mapped to its corresponding gene object and overlaid onto
a global molecular network developed from information
contained in the Ingenuity knowledge base. IPA network
analyses answer the question of what relationships exist
between the genes in the dataset. The networks were
ranked by a score according to how relevant they are to the
genes in the input dataset. The score takes into account the
number of focus genes in the network and the size of
the network to approximate how relevant this network is to
the original list of focus genes. The greater the number of
network eligible molecules in a network, the higher the
score (lower the P value) will be. The molecular and
cellular functions analysis identified the molecular and
cellular functions that were most significant to the dataset.
The toxicant functions analysis identified the xenobiotic
pathways that were most significant to the dataset. Fisher’s
exact test was used to calculate a P-value to determine the
probability that the association between the genes in the
pathways and the genes in each list is explained by chance
alone. A P B 0.05 was considered to be statistically sig-
nificant for overrepresentation of the molecules in a given
process.
Results
Blood Lead Levels in AU and TD
There were no significant differences in blood lead levels
between AU and TD (t-test, P = 0.97). The mean blood
lead level for AU was 1.30 ± 1.01 lg/dl (Mean ± SD),
and for TD was 1.30 ± 0.58 lg/dl (Mean ± SD). The
geometric mean blood lead level for AU was 1.03 lg/dl,
and for TD was 1.16 lg/dl. Blood lead levels ranged from
0.32 to 5.21 lg/dl in AU subjects, and ranged from 0.37 to
2.99 lg/dl in TD subjects. No blood lead level was higher
than 10 lg/dl in any subject. A log2-transformation was
applied to blood lead levels due to the skewed distribution
values in both AU and TD (Supplementary Fig. 1). The
distribution of the log2-transformed lead levels followed a
normal distribution (Kolmogorov–Smirnov Test P = 0.71,
0.92, and 0.89 for TD, AU and TD ? AU, respec-
tively).This resulted in a more linear relationship between
gene expression and blood lead levels.
Genes Whose Expression Correlated with Lead Levels
Figure 2 shows the total numbers of probe sets derived
from the ANCOVAs shown in Fig. 1 and shows how many
genes overlapped for each analysis. The ANCOVA anal-
ysis for TD showed that 1,712 probe sets significantly
(p(log2 Pb) B 0.05) correlated with log2 Pb levels (Fig. 2,
bottom left circle). The ANCOVA analysis for AU showed
1,829 probe sets that significantly (p(log2 Pb) B 0.05)
correlated with log2 Pb levels (Fig. 2, bottom right circle).
The ANCOVA analysis for AU and TD combined group
4 Neurotox Res (2011) 19:1–13
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showed that expression of 2,172 probe sets differed sig-
nificantly between the AU and TD groups as a function of
log2 Pb levels (p(diagnosis 9 log2 Pb) \ 0.05; Fig. 2, top
circle).
There were four gene lists that represented the different
overlaps for the ANCOVAs which are designated A, B, C,
and D in Fig. 1. The numbers of genes in each overlap area
are shown in Fig. 2.
Gene list A (Fig. 1) contained 48 probe sets (Fig. 2) that
overlapped the three ANCOVA models. The expression of
these genes significantly correlated with log2 Pb levels in
both the AU and TD groups (p(log2 Pb) B 0.05 for both
groups)—but the partial correlation coefficients were
significantly different from each other (p(diagnosis 9
log2 Pb) \ 0.05) (Supplementary Table 1). The 48 probe
sets represent 31 annotated genes and the partial correla-
tions for these genes are shown for the AU and TD groups
in Fig. 3. A number of human leukocyte antigen (HLA)
genes, including HLA-DRB subtype and the major histo-
compatibility complex (MHC) class II-associated invariant
chain CD74 are shown in the heat map. ANXA2 and
ANXA4, two calcium-dependent phospholipid binding
genes, are also shown (Fig. 3). Note that most of the genes
are negatively (blue) correlated with blood lead levels in
the TD subjects but positively (red) correlated with blood
lead levels in the AU subjects (Fig. 3). Only two genes,
TUBGCP3 and SH3BP2, are positively correlated with
blood lead levels in TD and negatively correlated in AU.
The partial correlations for three genes, ALDH3A2 and
PCDHB11 and AMN, were negatively correlated with
log2 Pb levels in TD and negatively correlated with log2 Pb
levels in AU, but were significantly different (p(diagno-
sis 9 log2 Pb) B 0.05) between the groups. The partial
correlations in Fig. 3 ranged from -0.72 to ?0.54 for TD
and from -0.47 to ?0.53 for AU. The microRNA targets
for these 48 genes are listed in Supplementary Table 2.
Gene list B (Fig. 1) contained 30 probe sets (Fig. 2) that
were shared between the TD and AU ANCOVAs. These 30
Fig. 2 Venn diagrams showing the numbers of probe sets obtained
for each of the analyses performed in Fig. 1. List A: Only 48 probe
sets were shared between the three ANCOVAs. These genes were
significantly correlated (p(log2 Pb) B 0.05) with lead levels in both
AU and TD groups, and were significantly different from each other
(p(Diagnosis 9 log2 Pb) B 0.05). List B: A total of 30 probe sets
were significantly correlated (P B 0.05) with lead levels in both the
AU and TD groups, and were not significantly different from each
other. List C: A total of 791 probe sets significantly correlated
(P B 0.05) with lead levels in TD (P B 0.05) (Supplementary
Table 4) but not in AU. List D: A total of 162 probe sets significantly
correlated (P B 0.05) with lead levels in AU (P B 0.05) (Supple-
mentary Table 5) but not in TD Fig. 3 A heat map of the partial correlations of the 31 annotated
genes that were represented by 48 probe sets identified in gene List A
in Fig. 2. Genes are shown in the rows, and diagnostic classes (AU
and TD) are in columns. Negative correlations are shown in blue and
positive correlations are shown in red (see calibration bar at bottom).
These genes represent those that significantly correlated with lead
levels in both AU and TD subjects (p(log2 Pb) B 0.05 for each
group). In addition, the partial correlation coefficients for these genes
were statistically significantly different between the TD and AU
subjects when the interaction of diagnosis and lead levels was
examined (p(Diagnosis 9 log2 Pb) \ 0.05). HLA-DRB* is the abbre-
viation for HLA-DRB1/2/3/4/5. IGH* is the abbreviation for IGH@/
A1/A2/G1/G3/M/V. (Color figure online)
Neurotox Res (2011) 19:1–13 5
123
probe sets represent those that were correlated with log2 Pb
levels in both AU and TD subjects, and were not statisti-
cally different (p(diagnosis 9 log2 Pb) [ 0.05). These
genes included the Aryl hydrocarbon receptor nuclear
translocator (ARNT), an ATPase family member (ATAD),
polyserase 3(POL3S), peroxiredoxin 2(PRDX2), dynein
(axonemal, light chain 1) (DNAL1), secretory carrier
membrane protein 1 (SCAMP1) and alpha synuclein
(SNCA) (Supplementary Table 3).
Gene list C (Fig. 1) had 791 probe sets (Fig. 2) that were
significantly correlated (P B 0.05) with blood lead levels
in the TD subjects but not in the AU subjects (Supple-
mentary Table 5). This is shown in the cluster in Fig. 4. Of
these 791 probe sets, a large number of probe sets (250) are
positively correlated (red) with blood lead levels and an
even larger number of probe sets (541) are negatively
correlated (blue) with blood lead levels in the TD subjects.
However, these probe sets showed no correlation with
blood lead levels in the AU subjects (Fig. 4). The gluta-
thione S-transferase gene (GSTT1) is in this list (Supple-
mentary Table 4) and negatively correlated with blood lead
levels in TD subjects (Partial correlation: -0.62).
Gene list D (Fig. 1) had 162 probe sets (Fig. 2) that
were significantly correlated (P B 0.05) with blood lead
levels in the AU subjects but not in the TD subjects
(Supplementary Tables 5). This is shown graphically in the
cluster in Fig. 5. Of these 162 probe sets, there are a
number of probe sets (76) that are positively correlated
(red) with lead levels in AU subjects; and a similar number
of probe sets (86) that are negatively correlated (blue) with
blood lead in the AU subjects. The partial correlations in
most of genes in the AU (Fig. 5, right column) subjects
tended to be inverse in sign to the partial correlations in the
TD subjects (Fig. 5, left column), though these were not
statistically significant (p(log2 Pb) [ 0.05).
Biological Significance
Network Functions of the Genes Whose Expression
Correlated Differently with Lead Levels in AU and TD
(List A)
An IPA network function analysis was performed for the
48 probe sets that correlated with blood lead levels in the
Fig. 4 A heat map showing the partial correlations of the 791 probe
sets identified in gene List C in Fig. 2. Probe sets are in rows and the
AU and TD diagnostic groups are in the columns. Negative
correlations are shown in blue and positive correlations are shown
in red (see calibration bar at bottom). These 791 probe sets represent
genes that significantly correlated (p(log2 Pb) B 0.05) with lead
levels in TD and not in AU subjects. Note high positive and negative
correlations in the TD group and lack of correlations in the AU group.
(Color figure online)
Fig. 5 A heat map showing the partial correlations of the 162 probe
sets identified in List D in Fig. 2. Probe sets are shown in the rows
and the AU and TD groups in the columns. Negative correlations are
shown in blue and positive correlations are shown in red (see
calibration bar at bottom). These 162 probe sets represent those that
significantly correlated (p(log2 Pb) B 0.05) with lead levels in
children with AU and not in TD subjects. Note high positive and
negative correlations in the AU group and modest inverse correlations
in the TD group. (Color figure online)
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AU and TD groups, but were significantly different
between the groups. Figure 6 illustrates the top network
which includes many genes involved in immunological and
inflammatory disease processes. Most of the genes in this
network showed a positive correlation with log2 Pb levels
in the AU subjects and a negative correlation with log2 Pb
levels in TD subjects. Only ALDH3A2 showed a negative
correlation in AU and positive correlation in TD.
Molecular and Cellular Function Analysis for All
of the Genes Whose Expression Correlated with Blood
Lead Levels Differently in AU and TD (Lists A, C, D)
Given that the genes that correlated with lead levels in AU
and TD were so different, it was of interest to know what
molecular functions and pathways are differentially affec-
ted. Thus, the three gene lists that represented the differ-
entially correlated genes in AU compared to TD (Fig. 2;
Lists A, C, D) were used as inputs for IPA analysis. We did
not include list B because these are the genes that correlate
with lead levels in a similar fashion in AU and TD subjects.
Table 1 lists the top five overrepresented molecular and
cellular functions for genes whose expression correlated
with blood lead levels differently in AU and TD (Lists A,
C, D). For genes that correlated with lead levels differently
in AU and TD (List A) many participate in cell–cell sig-
naling, antigen presentation, cell cycle, development and
growth, and proliferation (Table 1). The genes that corre-
lated with lead levels in TD (List C) were associated with
post-translational modification, protein synthesis, cell
morphology, cell-to-cell signaling and cellular assembly
and organization (Table 1). The genes that correlated with
lead levels in AU subjects (List D) were associated with
cellular compromise, drug metabolism, lipid metabolism,
small molecule biochemistry, and DNA replication,
recombination and repair (Table 1).
Xenobiotic Pathway Analysis for All Genes Whose
Expression Correlated with Blood Lead Levels
Differently in AU and TD (Lists A, C, D)
Figure 7 shows mitochondrial dysfunction pathways
(P = 0.014) were overrepresented in the 48 probe sets that
Fig. 6 The top network that came from the 48 probe sets that correlated
significantly (p(log2 Pb) B 0.05) with lead levels in both AU and TD,
but for which the correlation coefficients were significantly different
between the two groups (p(Diagnosis 9 log2 Pb) \ 0.05). This
network is associated with immunological and inflammatory disease
processes. AU (?) (Red) represents probe sets that positively correlated
with lead levels in AU. AU (–) (Blue) represent probe sets that
negatively correlated with lead levels in AU. (Color figure online)
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correlated with lead in AU and TD but were different
between the groups (List A). Fatty acid metabolism, PXR/
RXR activation, G2/M transition of the cell cycle
pathways, TR/RXR action, and LPS/IL-1meditated inhi-
bition of RXR function were overrepresented in the 791
probe sets that correlated with lead levels in TD subjects
(ranging from P = 0.039 to P = 0.00001) (List C). There
was no xenobiotic pathway significantly overrepresented in
the 162 probes that correlated with lead levels in AU
(mitochondrial dysfunction, P = 0.17) (List D).
Discussion
One of the most significant findings of this study is that the
expression of many genes correlated with circulating blood
lead concentrations even at low lead levels in AU and TD
children (List A, B, C, D). The finding that there are cor-
relations between expression of hundreds of genes in blood
with blood lead levels in both groups of children supports
the notion that increasing levels of lead, even at low levels,
are associated with differences of transcription in blood.
Thus, even low levels of lead may produce biological
effects in humans. Whether these are toxicological
responses or adaptive/protective responses may depend
upon the environmental context and genetic context in
which they occur.
The other significant finding of the study is that almost
all of the genes that correlated with lead levels in TD
subjects did not correlate in AU subjects. Moreover, almost
all of the genes that correlated with lead levels in AU
subjects did not correlate in TD subjects. Of the thousand
genes that correlated with lead in this study, only a very
Table 1 Molecular and cellular
functions analysis for genes
whose expression correlated
with blood lead levels
differently in AU and TD
subjects (Lists A, C, D)
This table shows the top five
overrepresented molecular and
cellular functions for each gene
list
Category P value Number of
molecules
Gene list A: 48 probe sets differently correlated with lead levels in AU and TD
1 Cell-to-cell signaling and interaction 7.27E-06–4.62E-02 11
2 Antigen presentation 5.73E-05–4.16E-02 7
3 Cell cycle 5.73E-05–4.59E-02 5
4 Cellular development 3.81E-04–4.93E-02 8
5 Cellular growth and proliferation 5.2E-04–4.97E-02 9
Gene list C: 791 probe sets only correlated with lead levels in TD
1 Post-translational modification 7.39E-05–3E-02 13
2 Protein synthesis 7.39E-05–3E-02 41
3 Cell morphology 9.86E-05–3E-02 42
4 Cell-to-cell signaling and interaction 2.58E-04–3E-02 29
5 Cellular assembly and organization 2.58E-04–3E-02 46
Gene list D: 162 probe sets only correlated with lead levels in AU
1 Cellular compromise 8.6E-04–3.21E-02 7
2 Drug metabolism 1.27E-03–4.46E-02 4
3 Lipid metabolism 1.27E-03–4.46E-02 12
4 Small molecule biochemistry 1.27E-03–4.46E-02 16
5 DNA replication, recombination, and repair 1.46E-03–3.21E-02 9
Fig. 7 Xenobiotic pathway analyses for genes whose expression
correlated with lead levels differently in AU compared to TD (List A,
C, D). (I). Mitochondrial dysfunction pathways (MD) were overrep-
resented for gene list A. These 48 probe sets represented genes whose
expression correlated with lead levels in both AU and TS groups, but
the partial correlation coefficients were statistically different from
each other. (II) Pathways that were overrepresented in gene list C that
had 791 probe sets whose expression correlated with lead levels in
TD, but not AU. LPS/IL1: lipopolysaccharide and interleukin
pathways. TR/RXR: thyroid hormone receptor (TR)/retinoic acid
receptor (RXR) activation. G2/M: cell cycle transition and cell cycle
pathways. PXR/RXR: pregnane X receptor (PXR)/retinoic acid
receptor activation. FAM: fatty acid metabolism pathways. There
were no statistically significant xenobiotic pathways detected in
children with AU. (Color figure online)
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few (n = 78, list A ? list B) overlap between AU and
controls. Even among these few genes that correlate with
lead levels and are regulated in AU and controls, the
majority of the partial correlation coefficients (n = 48, list
A) are statistically different from one another. Thus, the
data show that the association of gene transcription with
lead levels differs in children with AU compared to
controls.
A major question, therefore, is whether this has any
relationship to symptoms of AU. The present data cannot
provide the answer. Lead levels have been declining stea-
dily in the environment since the late 1970s when lead
additives to gasoline were phased out, whereas the inci-
dence of AU has been rising since then (Hertz-Picciotto
and Delwiche 2009). Thus, lead probably does not account
for the increasing incidence of AU. In our another study,
the correlation of gene expression with mercury levels in
children with AU is also very different from matched
controls (Stamova et al. submitted). Thus, the associations
between transcription and levels for both heavy metals
differ in AU compared to TD, suggesting there is not a
specific abnormality associated with a given heavy metal.
Though it is difficult to ascribe cause or effect, individuals
with AU may have different genetic backgrounds from
controls, and that when presented with a heavy metal like
lead have different transcriptional programs. If this is the
case, then the differing transcriptional programs following
exposure to lead (and mercury) in children with AU and
TD controls are likely to be adaptive in order to success-
fully deal with the heavy metal. Other explanations, how-
ever, cannot be ruled out: differences in exposures,
epigenetic marks or risk factors like parental age. Though it
seems unlikely that the findings of this study directly
relate to the symptoms of AU, it is unknown whether
these different transcriptional programs might influence
the phenotypic variation in AU or even in TD controls
(Tang et al. 2004).
Blood Lead Levels
There were no significant differences in blood lead levels
between children with AU and controls in this study. The
geometric mean blood lead level for AU was 1.03 lg/dl,
and for TD was 1.16 lg/dl. These are a little below the
national average of 1.9 lg/dl (geometric mean) for 1- to
5-year old children in the United States in 1999–2004
(Jones et al. 2009). No blood lead level was above the lead
toxicity threshold of 10 lg/dl established by the United
States Centers for Disease Control and Prevention (CDC).
Thus, any correlations between gene expression and lead
levels are not due to high levels of lead in this study.
Although blood lead levels in children have been declining
in the United States since late 1970s, some authors have
suggested that there is no ‘‘safe level’’ of lead and that
neurobehavioral deficits and learning impairments occur
even when blood lead levels are below 10 lg/dl (Lanphear
2007; Needleman 2009; Needleman 2004; Needleman and
Landrigan 2004; Rossi 2008; Lanphear et al. 2005). Our
data provide evidence for a correlation between gene
expression and blood lead levels below 10 lg/dl in blood
of humans.
Functions of Genes Whose Expression Correlated
with Lead Levels Differently in AU and TD (List A)
Of the 48 probe sets that significantly correlated with
log2 Pb levels in both AU and TD groups, but the partial
correlation coefficients were statistically different, many
were associated with immunological and inflammatory
processes (Fig. 3). In the CNS, lead treated rat astrocytes
express a number of pro-inflammatory cytokines including
IL-1b, IL-6, and TNFa (Struzynska et al. 2007). In human
peripheral mononuclear cells, lead regulates TNF-alpha
and TNF-alpha receptor expression (Guo et al. 1996). For
the top network identified for the 48 probe sets differen-
tially regulated between AU and TD, TNF was central to
the pathway—though TNF RNA levels themselves were
unchanged. Notably, lead is reported to produce immuno-
modulatory effects by increasing MHC molecule surface
expression in both murine (Ia) and human HLA antigen
presenting cells (Guo et al. 1996; McCabe and Lawrence
1991). Thus, the correlations of HLA subtype gene levels
with lead levels in our study support these previous
findings.
Dysregulation of the immune response has also been
associated with AU. Abnormal cytokine levels, immuno-
globulin levels, complement levels, and decreased lym-
phocyte numbers have been described in children with AU
(Ashwood et al. 2006; Warren et al. 1997; Warren et al.
1996; Gupta et al. 1996; Singh and Rivas 2004; McCabe
et al. 1991; Corbett et al. 2007). In addition, HLA-DRB1
and complement C4 alleles are also associated with AU
(Ashwood et al. 2006; Warren et al. 1997; Warren et al.
1996; Gupta et al. 1996). The HLA system plays a central
role in immune function. In humans, peptide antigens are
presented to T cells in the context of HLA molecules
(Nepom and Erlich 1991). We found several HLA genes
that correlated with lead levels differently in AU compared
to TD subjects. These included HLA-DRB subtypes and
the MHC class II-associated invariant chain CD74 which is
associated with intracellular sorting of MHC class II mol-
ecules (Fig. 3). In addition, the antigen presentation func-
tion was overrepresented in gene list A (Table 1). These
immune genes and pathways that correlate differently with
lead levels in AU compared to TD controls could indicate:
(1) the immune aberration observed in AU might be due in
Neurotox Res (2011) 19:1–13 9
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part to lead or another toxicant; (2) different immune
responses in AU compared to TD controls may alter the
transcriptional association to various environmental factors
including lead in these groups; (3) lead or other toxicants
may interact with the underlying genetic background in AU
and predispose to immune dysfunction.
Lead competes with calcium and zinc for binding sites
on proteins, and thus affects a variety of cellular pathways
and downstream gene expression (Bouton and Pevsner
2000). In our study, two annexin protein members, ANXA2
and ANXA4, correlated with lead levels in both AU and
TD, and the partial correlations were significantly different
in AU and TD. Annexins are a family of calcium-depen-
dent phospholipid binding proteins which are involved in
signal transduction and other cellular processes. Expression
of ANXA1 and ANXA5 increase in lead-exposed astro-
cytes, and ANXA5 can be directly bound and activated by
nanomolar concentrations of lead (Bouton et al. 2001).
Since all members of the annexin protein family have
similar functional and structural domains as those in
ANXA1 and ANXA5, lead may also competitively bind
ANXA2 and ANXA4 and influence signal transduction. Of
interest in AU, ANXA4 and ANXA5 are important in the
maintenance of pregnancy by preventing activation of
blood coagulation. Recent data suggest that ANXA4 enters
the blood just after pregnancy probably to prevent coagu-
lation, and ANXA5 is expressed in the placenta probably to
prevent coagulation (Masuda et al. 2004). ANXA4 inhibits
Staphylococcus aureus attachment to human macrophages
and may play a role in other infections (Gotoh et al. 2005).
The xenobiotic pathway analyses showed that mito-
chondrial dysfunction was overrepresented for genes
whose expression correlated with lead levels differently in
AU and TD (List A, Supplementary Table 1). Mitochon-
dria play a central role in energy metabolism and other
functions including cell death, cell proliferation, steroid
synthesis, heme synthesis and calcium signaling (McBride
et al. 2006; Green 1998; Rossier 2006). Lead exposure
alters the mitochondrial structure in tissues taken from
lead-intoxicated animals and in human biopsy specimens
(Goyer 1968; Goyer et al. 1968). Competing with calcium,
lead is taken up into mitochondria in an energy dependent
manner (Walton 1973; Walton and Buckley 1977; Kapoor
et al. 1985). Future studies are needed to determine if the
differences in expression of the mitochondrial genes that
correlate with lead in AU compared to control children
translate into dys-regulated mitochondrial function in AU.
Functions of Genes Whose Expression Correlated
with Blood Lead Levels in AU or TD (Lists C and D)
Our data also show that several xenobiotic pathways are
overrepresented in genes correlating only with lead levels
in TD controls, including fatty acid metabolism, PXR/RXR
activation, G2/M transition of the cell cycle pathways, TR/
RXR action, LPS/IL-1meditated inhibition of RXR func-
tion (Fig. 7). Of interest, there were no statistically sig-
nificant toxicant pathways detected in children with AU
(Fig. 7), as opposed to TD children who had many such
xenobiotic pathways.
Fatty acids are an integral part of cell membranes and
are an energy reserve for cells. Lead can alter fatty acid
composition and lipid peroxidation in animal liver
(Knowles and Donaldson 1996; Lawton and Donaldson
1991) and fatty acids are implicated in neurodevelopmental
disorders including AU (Richardson and Ross 2000; Wiest
et al. 2009). In earlier work from the CHARGE study, we
found that plasma fatty acid profiles in children with AU
differed from controls (Wiest et al. 2009). This study
shows that fatty acid metabolism genes correlated with lead
levels in TD and not in AU which may provide additional
support for fatty acid metabolism abnormalities in AU.
Notably, 12 molecules correlated with lipid metabolism in
AU but not TD subjects (Table 1), further suggesting
dysfunction of lipid and fatty metabolism in AU compared
to TD subjects.
GSTT1 expression, which correlated with lead levels in
TD but not AU subjects (Supplementary Table 4), is
involved in LPS/IL-1 meditated inhibition of RXR function
pathway in our study. GSTs are a family of enzymes that
catalyze the conjugation of reduced glutathione to a variety
of electrophilic and hydrophobic compounds (Wright et al.
1998). GSTs are major mediators of cellular responses to
toxicants and stress (Bouton and Pevsner 2000; Qu et al.
2002). The expression of a number of GST isoforms
changes in response to both acute and chronic lead expo-
sure (Daggett et al. 1998; Oberley et al. 1995; Moser et al.
1995). GST-P is induced in rat liver and kidney by lead,
and the activation of the GST-P gene is mediated in part by
TDEI and AP-1 (Suzuki et al. 1996). In the kidney, the
increase in GST by lead precedes cellular damage, and thus
may serve as a biomarker of lead exposure (Wright et al.
1998). GSTT1 was also significantly increased in metal-
lothionein (MT)-null mice after lead exposure (Qu et al.
2002). Though GSTT1 expression correlates with lead
levels in TD but not AU subjects in this study, the signif-
icance of this is uncertain.
Genes that Correlate Similarly with Lead Levels
in Both AU and TD (List B)
Prior to this study, one might well have hypothesized that
the transcriptome that correlated with lead levels in AU and
TD subjects would be the same. Thus, finding only 30
transcripts correlate similarly with lead levels in both AU
and TD subjects does not support this hypothesis.
10 Neurotox Res (2011) 19:1–13
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However, the genes that do correlate with lead in both
groups are of interest. Dynein, which correlated with lead
levels in both groups, is one of the microtubule-based
motors (Rubinsztein et al. 2005) and might be affected by
heavy metals—though this does not appear to have been
studied. Of more interest, alpha synuclein expression
negatively correlates with lead levels in both TD subjects
(Partial correlation = -0.62) and in AU subjects (Partial
correlation = -0.32). This protein has been implicated in
the degenerative synucleinopathies of brain including
Parkinsons disease and Alzheimer’s disease (Eller and
Williams 2009; Jellinger 2009; Crews et al. 2009), and
heavy metals like lead have been sometimes been impli-
cated in these conditions (White et al. 2007).
Limitations of the Study
It is important to emphasize that the current data must be
interpreted with caution. Though the age, gender, and race
were similarly matched, our group sizes were small with
unequal numbers of subjects in each group. This could
underlie some differences between the groups. Since the
data are cross-sectional, it is impossible to draw strong
conclusions about any of the associations observed unless
increases and decreases of lead levels over time were
shown to be correlated with increases and decreases of
gene expression over time. Since this is a one-time study,
the correlation of an individual gene might not be repli-
cated in future studies due to stochasticity.
Of equal concern, other differences between cases and
controls are possible, and adjustment for those differences
would alter the findings. We have reported differences in
lipid metabolism, sleep patterns, and pesticide exposures of
cases versus controls in the CHARGE Study (Wiest et al.
2009; Krakowiak et al. 2008). These differences may be
confounding the relationships of gene expression to lead
that might differ in AU and TD groups.
Another limitation of the study is that the circulating
lead represents a small fraction of the body burden. The
largest store of lead is in bone where it turns over slowly.
Thus, the transcriptional associations with lead levels in
blood probably do not reflect those in the bone, and
probably do not reflect those in brain and other organs.
Finally, an unresolved issue was how best to correct for
multiple comparisons. The Benjamini-Hochberg False
Discovery (FDR) rate approach is most commonly used for
such corrections in microarray studies because of the very
large number of variables. However, the FDR has short-
comings since it assumes all genes are independently
expressed, which is not the case (Zhang 2006). Thus, we
chose to use two criteria to decrease the numbers of false
positive genes: partial correlations had to have a P B 0.05
level using an ANCOVA; and the identified significant
genes had to overlap for at least two of the ANCOVAs
performed. However, if one simply ignores any correction
for multiple comparisons, then 1,712 genes correlated with
lead in TD and 1,829 genes correlated with lead in AU, but
only 78 genes were shared between the two analyses. By
not correcting for multiple comparisons, this should max-
imize the genes that overlapped between AU and TD which
in this case is 78 out of [1,000 genes. Thus, the major
conclusion of the study is unchanged whether a correction
for multiple comparisons is applied or not. The conclusion
is: almost all of the genes whose expression correlates with
lead levels in children with AU differ from those that
correlate with lead levels in TD children.
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